



HARVARD MEDICAL SCHOOL

ACTIVITY DISCLOSURE STATEMENT Advances in Cytology and Small Biopsies 732036-2302 6/12/23-6/14/23

Accreditation

In support of improving patient care, Harvard Medical School is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Accreditation

The Harvard Medical School designates this live activity for a maximum of 25.00 *AMA PRA Category 1 Credits*[™]. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

All individuals in a position to control the content of this activity have been asked to disclose any relationship they have with ineligible companies whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.

The following planners, speakers, and content reviewers have reported relevant financial relationship(s) with ineligible companies whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients. All of the relevant financial relationships listed for these individuals have been mitigated:

NAME	COMPANY	RELATIONSHIP
<i>Course Faculty:</i>		
<i>Sarah Feldman, MD</i>	<i>UpToDate</i>	<i>Royalty or Intellectual Property Rights</i>
<i>David Hwang, MD</i>	<i>Carelon</i>	<i>Consultant</i>
<i>Lynette Sholl, MD</i>	<i>Genentech</i>	<i>Research Support, Consultant</i>
	<i>Lilly</i>	<i>Consultant</i>
	<i>AstraZeneca</i>	<i>Advisory Board/Committee</i>
	<i>GV20 Therapeutics</i>	<i>Consultant</i>
	<i>Bristol Myers Squibb</i>	<i>Research Support</i>
<i>Paul VanderLann, MD, PhD</i>	<i>Gala Therapeutics</i>	<i>Consultant</i>
	<i>Galvanize Therapeutics</i>	<i>Consultant</i>
	<i>Intuitive Surgical</i>	<i>Consultant</i>
	<i>Ruby Robotics</i>	<i>Consultant</i>

All other individuals including course directors, planners, reviewers, faculty, staff, etc., who are in a position to control the content of this educational activity have reported no relevant financial relationships with ineligible companies whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.